253 related articles for article (PubMed ID: 33069924)
1. Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event.
Deligiorgi MV; Trafalis DT
Int Immunopharmacol; 2020 Dec; 89(Pt B):107050. PubMed ID: 33069924
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS.
Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
J Endocrinol Invest; 2022 Nov; 45(11):2131-2137. PubMed ID: 35870109
[TBL] [Abstract][Full Text] [Related]
3. A Case of Cancer-Associated Hyponatraemia: Primary Adrenal Insufficiency Secondary to Nivolumab.
Galliazzo S; Morando F; Sartorato P; Bortolin M; De Menis E
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):363-366. PubMed ID: 34238203
[TBL] [Abstract][Full Text] [Related]
4. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency.
Husebye ES; Allolio B; Arlt W; Badenhoop K; Bensing S; Betterle C; Falorni A; Gan EH; Hulting AL; Kasperlik-Zaluska A; Kämpe O; Løvås K; Meyer G; Pearce SH
J Intern Med; 2014 Feb; 275(2):104-15. PubMed ID: 24330030
[TBL] [Abstract][Full Text] [Related]
5. Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer.
Kagoshima H; Hori R; Kojima T; Okanoue Y; Fujimura S; Taguchi A; Shoji K
Auris Nasus Larynx; 2020 Apr; 47(2):309-313. PubMed ID: 31235078
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
J Immunother; 2020 Jan; 43(1):38-42. PubMed ID: 31567704
[TBL] [Abstract][Full Text] [Related]
8. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
Messer A; Drozd B; Glitza IC; Lu H; Patel AB
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab Induced Adrenal Insufficiency: Rare Side-effect of a New Anti-cancer Therapy - Immune-checkpoint Inhibitors.
Rai M; Go M
Cureus; 2020 Apr; 12(4):e7625. PubMed ID: 32399358
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor-Induced Adrenalitis and Primary Adrenal Insufficiency: Systematic Review and Optimal Management.
Shi Y; Shen M; Zheng X; Yang T
Endocr Pract; 2021 Feb; 27(2):165-169. PubMed ID: 33554872
[TBL] [Abstract][Full Text] [Related]
11. Adrenal Insufficiency: Immune Checkpoint Inhibitors and Immune-Related Adverse Event Management.
Hobbs KB; Yackzan S
Clin J Oncol Nurs; 2020 Jun; 24(3):240-243. PubMed ID: 32441673
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
13. Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects.
Martella S; Lucas M; Porcu M; Perra L; Denaro N; Pretta A; Deias G; Willard-Gallo K; Parra HS; Saba L; Scartozzi M; Wekking D; Kok M; Aiello MM; Solinas C
Semin Oncol; 2023 Dec; 50(6):144-148. PubMed ID: 38151399
[TBL] [Abstract][Full Text] [Related]
14. An Addison disease revealed with a serious hyponatremia.
Maguet H; Carreau A; Hautefeuille S; Bonnin P; Beaune G
Ann Biol Clin (Paris); 2017 Feb; 75(1):87-91. PubMed ID: 28132947
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-Related Pneumonitis.
Gomatou G; Tzilas V; Kotteas E; Syrigos K; Bouros D
Respiration; 2020; 99(11):932-942. PubMed ID: 33260191
[TBL] [Abstract][Full Text] [Related]
16. Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency.
Falorni A; Laureti S; De Bellis A; Zanchetta R; Tiberti C; Arnaldi G; Bini V; Beck-Peccoz P; Bizzarro A; Dotta F; Mantero F; Bellastella A; Betterle C; Santeusanio F;
J Clin Endocrinol Metab; 2004 Apr; 89(4):1598-604. PubMed ID: 15070918
[TBL] [Abstract][Full Text] [Related]
17. Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report.
Harada M; Naoi H; Yasuda K; Ito Y; Kagoo N; Kubota T; Ichijo K; Mochizuki E; Uehara M; Matsuura S; Tsukui M; Koshimizu N
BMC Pulm Med; 2021 Jan; 21(1):6. PubMed ID: 33407304
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
Hasegawa T; Ozaki Y; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Muto S; Okabe N; Higuchi M; Shio Y; Suzuki H
J Med Case Rep; 2019 Oct; 13(1):316. PubMed ID: 31647029
[TBL] [Abstract][Full Text] [Related]
19. Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience.
Zhao JJ; Kumarakulasinghe NB; Muthu V; Lee M; Walsh R; Low JL; Choo J; Tan HL; Chong WQ; Ang Y; Chan G; Yong WP; Huang Y; Ngoi N; Wong A
Oncology; 2021; 99(3):192-202. PubMed ID: 33440374
[TBL] [Abstract][Full Text] [Related]
20. Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy.
Deligiorgi MV; Siasos G; Vergadis C; Trafalis DT
Int Immunopharmacol; 2020 Jun; 83():106427. PubMed ID: 32244049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
